Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 814

Similar articles for PubMed (Select 19395730)

1.

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C.

Nephrol Dial Transplant. 2009 Sep;24(9):2792-6. doi: 10.1093/ndt/gfp191. Epub 2009 Apr 25.

2.

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.

Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C.

Nephrol Dial Transplant. 2009 Mar;24(3):948-55. doi: 10.1093/ndt/gfn571. Epub 2008 Oct 13.

3.

Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients.

Salahudeen AK, Dykes P, May W.

Nephrol Dial Transplant. 2003 Jul;18(7):1339-44.

4.

Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients.

Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY.

Nephrol Dial Transplant. 2004 Feb;19(2):457-62.

5.

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M.

N Engl J Med. 2008 Aug 7;359(6):584-92. doi: 10.1056/NEJMoa0706130.

6.

Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients.

Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA.

Nephrol Dial Transplant. 2010 Aug;25(8):2679-85. doi: 10.1093/ndt/gfq089. Epub 2010 Feb 22.

7.

The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients.

Park SY, Jeong KH, Moon JY, Lee SH, Ihm CG, Rhee SY, Woo JT, Oh IH, Lee TW.

Clin Exp Nephrol. 2010 Jun;14(3):239-43. doi: 10.1007/s10157-010-0272-5. Epub 2010 Apr 8.

PMID:
20376517
8.

Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis.

Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K.

Int Urol Nephrol. 2008;40(4):1067-74. doi: 10.1007/s11255-008-9462-4. Epub 2008 Sep 13.

PMID:
18791804
9.

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.

Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R; RISCAVID Study Group.

Nephrol Dial Transplant. 2008 Jul;23(7):2337-43. doi: 10.1093/ndt/gfm951. Epub 2008 Feb 27.

10.

Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.

Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR.

Kidney Int. 2006 Jul;70(2):351-7. Epub 2006 May 31.

PMID:
16738536
11.

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.

Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M.

Nephrol Dial Transplant. 2010 Aug;25(8):2672-9. doi: 10.1093/ndt/gfq053. Epub 2010 Feb 18.

12.

Predictors of mortality in long-term haemodialysis patients with a low prevalence of comorbid conditions.

De Lima JJ, Sesso R, Abensur H, Lopes HF, Giorgi MC, Krieger EM, Pileggi F.

Nephrol Dial Transplant. 1995;10(9):1708-13.

PMID:
8559493
13.

Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients.

Okuno S, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y, Yamakawa T, Inaba M, Nishizawa Y.

Nephrol Dial Transplant. 2009 Feb;24(2):571-7. doi: 10.1093/ndt/gfn521. Epub 2008 Sep 17.

14.

Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.

Hsu HJ, Wu MS.

Am J Med Sci. 2009 Feb;337(2):116-22. doi: 10.1097/MAJ.0b013e3181815498.

PMID:
19214027
15.

Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?

Peiskerová M, Kalousová M, Kratochvílová M, Dusilová-Sulková S, Uhrová J, Bandúr S, Malbohan IM, Zima T, Tesar V.

Kidney Blood Press Res. 2009;32(4):276-83. doi: 10.1159/000243050. Epub 2009 Oct 1.

PMID:
19797911
16.

Is there any survival advantage of obesity in Southern European haemodialysis patients?

Chazot C, Gassia JP, Di Benedetto A, Cesare S, Ponce P, Marcelli D.

Nephrol Dial Transplant. 2009 Sep;24(9):2871-6. doi: 10.1093/ndt/gfp168. Epub 2009 Apr 15.

18.

Association of mineral metabolism with an increase in cellular adhesion molecules: another link to cardiovascular risk in maintenance haemodialysis?

Arici M, Kahraman S, Gençtoy G, Altun B, Kalyoncu U, Oto A, Kirazli S, Erdem Y, Yasavul U, Turgan C.

Nephrol Dial Transplant. 2006 Apr;21(4):999-1005. Epub 2005 Dec 2.

19.

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M.

Kidney Int. 2005 Mar;67(3):1171-8.

PMID:
15698459
20.

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.

J Am Soc Nephrol. 2005 Jul;16(7):2205-15. Epub 2005 May 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk